Published in Proc Natl Acad Sci U S A on September 22, 2008
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci (2013) 3.16
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.73
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 2.67
A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep (2013) 1.92
T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol (2009) 1.78
Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol (2012) 1.66
Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron (2015) 1.57
Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia (2010) 1.54
Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol (2010) 1.52
How do immune cells support and shape the brain in health, disease, and aging? J Neurosci (2013) 1.51
CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol (2009) 1.43
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
The immunology of neurodegeneration. J Clin Invest (2012) 1.41
Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells. Physiol Rev (2011) 1.40
Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm (2014) 1.35
Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun (2010) 1.34
Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A (2009) 1.33
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29
Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol (2013) 1.23
Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm (Vienna) (2010) 1.22
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci U S A (2013) 1.17
Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation (2010) 1.13
Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis (2012) 1.12
Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol (2014) 1.12
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci (2010) 1.12
Glial cells in amyotrophic lateral sclerosis. Exp Neurol (2014) 1.11
Glial cells in amyotrophic lateral sclerosis. Neurol Res Int (2011) 1.08
Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis (2012) 1.07
The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener (2012) 1.06
The Role of immune and inflammatory mechanisms in ALS. Curr Mol Med (2011) 1.05
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics (2015) 1.05
Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet (2013) 1.03
Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal (2012) 1.01
Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci (2014) 1.00
Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 1.00
Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One (2011) 1.00
Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases. CNS Neurol Disord Drug Targets (2013) 0.98
Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction? Mol Psychiatry (2010) 0.97
CD 4+ T cells in the pathobiology of neurodegenerative disorders. J Neuroimmunol (2009) 0.97
Excess circulating alternatively activated myeloid (M2) cells accelerate ALS progression while inhibiting experimental autoimmune encephalomyelitis. PLoS One (2011) 0.96
Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS. Stem Cells (2014) 0.96
A conceptual revolution in the relationships between the brain and immunity. Brain Behav Immun (2010) 0.95
Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry (2013) 0.95
Effects of diabetes mellitus on amyotrophic lateral sclerosis: a systematic review. BMC Res Notes (2014) 0.95
Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm (Vienna) (2010) 0.93
Immunolocalization of influenza A virus and markers of inflammation in the human Parkinson's disease brain. PLoS One (2011) 0.93
Vector-free and transgene-free human iPS cells differentiate into functional neurons and enhance functional recovery after ischemic stroke in mice. PLoS One (2013) 0.93
Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J Neuroinflammation (2011) 0.92
CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest (2009) 0.92
The wobbler mouse, an ALS animal model. Mol Genet Genomics (2013) 0.92
Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res (2009) 0.92
Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis. J Cell Mol Med (2010) 0.91
T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation (2014) 0.91
Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Front Cell Neurosci (2013) 0.90
The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci (2014) 0.90
Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PLoS One (2012) 0.90
The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells. Neurol Res Int (2012) 0.90
Neuroinflammation in motor neuron disease. Nagoya J Med Sci (2015) 0.89
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88
Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl Neurodegener (2014) 0.86
Glial modulators as potential treatments of psychostimulant abuse. Adv Pharmacol (2014) 0.86
Regulatory T cells in CNS injury: the simple, the complex and the confused. Trends Mol Med (2011) 0.86
Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav (2012) 0.86
Cerebral nitric oxide represses choroid plexus NFκB-dependent gateway activity for leukocyte trafficking. EMBO J (2015) 0.86
Rapamycin increases survival in ALS mice lacking mature lymphocytes. Mol Neurodegener (2013) 0.86
Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS One (2011) 0.85
Impact of acute inflammation on spinal motoneuron synaptic plasticity following ventral root avulsion. J Neuroinflammation (2010) 0.85
The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.85
Intraspinal bone-marrow cell therapy at pre- and symptomatic phases in a mouse model of amyotrophic lateral sclerosis. Stem Cell Res Ther (2016) 0.85
Activated microglia provide a neuroprotective role by balancing glial cell-line derived neurotrophic factor and tumor necrosis factor-α secretion after subacute cerebral ischemia. Int J Mol Med (2012) 0.84
Adoptive transfer of Th1-conditioned lymphocytes promotes axonal remodeling and functional recovery after spinal cord injury. Cell Death Dis (2012) 0.84
Levels of soluble platelet endothelial cell adhesion molecule-1 and P-selectin are decreased in children with autism spectrum disorder. Biol Psychiatry (2012) 0.84
CD4 + T Cells and Neuroprotection: Relevance to Motoneuron Injury and Disease. J Neuroimmune Pharmacol (2015) 0.83
Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis. Front Cell Neurosci (2013) 0.83
The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One (2013) 0.83
BAFF controls neural cell survival through BAFF receptor. PLoS One (2013) 0.83
Eosinophil-derived neurotoxin is elevated in patients with amyotrophic lateral sclerosis. Mediators Inflamm (2013) 0.83
Myelosuppressive conditioning using busulfan enables bone marrow cell accumulation in the spinal cord of a mouse model of amyotrophic lateral sclerosis. PLoS One (2013) 0.82
SOD1(G93A) transgenic mouse CD4(+) T cells mediate neuroprotection after facial nerve axotomy when removed from a suppressive peripheral microenvironment. Brain Behav Immun (2014) 0.82
Humoral factors in ALS patients during disease progression. J Neuroinflammation (2015) 0.81
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 mice. J Neuroimmunol (2009) 0.81
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? Brain Res (2014) 0.80
Highly efficient differentiation of neural precursors from human embryonic stem cells and benefits of transplantation after ischemic stroke in mice. Stem Cell Res Ther (2013) 0.80
Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics (2015) 0.79
Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Br J Pharmacol (2017) 0.78
Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation (2016) 0.78
Effects of erythropoietin on adipose tissue: a possible strategy in refilling. Plast Reconstr Surg Glob Open (2015) 0.78
Amyotrophic lateral sclerosis: applications of stem cells - an update. Stem Cells Cloning (2010) 0.78
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics (2016) 0.78
Effects of facial nerve axotomy on Th2-associated and Th1-associated chemokine mRNA expression in the facial motor nucleus of wild-type and presymptomatic SOD1 mice. J Neurodegener Regen (2009) 0.78
Splenocytes derived from young WT mice prevent AD progression in APPswe/PSENldE9 transgenic mice. Oncotarget (2015) 0.78
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell (1992) 17.50
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron (2006) 7.82
Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci (2007) 7.42
Amyotrophic lateral sclerosis. N Engl J Med (2001) 7.37
Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci (2007) 6.23
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med (2007) 5.87
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 4.52
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci (2007) 2.56
Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci (2007) 2.53
Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci (2003) 2.52
SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest (2008) 2.42
Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve (2002) 2.25
Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2004) 2.21
Microglial phenotype: is the commitment reversible? Trends Neurosci (2006) 2.18
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int (2007) 2.11
Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 2.01
CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation. J Neurosci (2004) 1.71
A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci U S A (1996) 1.68
The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci (2005) 1.56
CD4+ T, but not CD8+ or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. Brain Behav Immun (2003) 1.46
Cu/Zn superoxide dismutase plays important role in immune response. J Immunol (2003) 1.32
Brain-derived neurotrophic factor supports facial motoneuron survival after facial nerve transection in immunodeficient mice. Brain Behav Immun (2005) 1.20
T cells contribute to lysophosphatidylcholine-induced macrophage activation and demyelination in the CNS. Glia (2007) 1.11
Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. J Neurol Sci (2006) 0.99
Controlled autoimmunity in CNS maintenance and repair: naturally occurring CD4+CD25+ regulatory T-Cells at the crossroads of health and disease. Neuromolecular Med (2005) 0.97
Therapeutic T cell-based vaccination for neurodegenerative disorders: the role of CD4+CD25+ regulatory T cells. Ann N Y Acad Sci (2005) 0.86
Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 4.52
Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn (2012) 3.54
Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med (2007) 3.33
Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol (2004) 2.46
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol (2013) 2.43
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol (2009) 2.22
T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol (2009) 1.78
Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol (2012) 1.66
The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci (2005) 1.56
Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol (2006) 1.54
Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia (2010) 1.54
Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem (2007) 1.52
A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options. J Neurol Sci (2003) 1.49
Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem (2006) 1.48
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun (2010) 1.34
Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol (2004) 1.33
Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res (2005) 1.27
Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol (2013) 1.23
Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol (2006) 1.21
Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.19
Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells. Mol Cell Biol (2006) 1.16
Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis (2012) 1.07
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics (2015) 1.05
Predictability of disease progression in amyotrophic lateral sclerosis. Muscle Nerve (2006) 1.03
Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem (2003) 1.03
Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res (2003) 1.00
Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol (2003) 0.99
Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res (2002) 0.97
Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol (2002) 0.96
Excess circulating alternatively activated myeloid (M2) cells accelerate ALS progression while inhibiting experimental autoimmune encephalomyelitis. PLoS One (2011) 0.96
Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals. Toxicology (2004) 0.93
Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun (2006) 0.93
Incidence and characteristics of spinal decompression surgery after the onset of symptoms of amyotrophic lateral sclerosis. Neurosurgery (2005) 0.88
Novel insights into the molecular mechanisms of α-fetoprotein expression and malignant phenotypes of hepatocellular carcinoma. Cell Mol Immunol (2011) 0.88
Inflammation in Parkinson's disease: cause or consequence? Mov Disord (2012) 0.85
Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology (2012) 0.85
ALSFRS and appel ALS scores: discordance with disease progression. Muscle Nerve (2008) 0.84
Analysis of multiple Invs transcripts in mouse and MDCK cells. Genomics (2004) 0.82
Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 0.82
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin (2014) 0.82
PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients. J Neuropathol Exp Neurol (2003) 0.81
Mutant genes responsible for Parkinson's disease. Curr Opin Pharmacol (2004) 0.81
Trauma, TDP-43, and amyotrophic lateral sclerosis. Muscle Nerve (2010) 0.81
Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol (2010) 0.80
TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. Acta Neuropathol Commun (2014) 0.80
Sublethal dose of 4-hydroxynonenal reduces intracellular calcium in surviving motor neurons in vivo. Acta Neuropathol (2005) 0.79
Serum anti-Fas antibody levels in amyotrophic lateral sclerosis. J Neuroimmunol (2003) 0.79
2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev Proteomics (2006) 0.79
Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun (2009) 0.78
Analysis of Gait Rhythm Fluctuations for Neurodegenerative Diseases by Phase Synchronization and Conditional Entropy. IEEE Trans Neural Syst Rehabil Eng (2015) 0.78
"Individual and health-related quality of life assessment in amyotrophic lateral sclerosis patients and their caregivers" by Lo Coco G, Lo Coco D, Cicero V, Oliveri A, Lo Verso G, Piccolo F, La Bella V. J Neurol Sci (2005) 0.78
Neuroprotective activities of regulatory T cells. Trends Mol Med (2011) 0.78
Mechanisms of disease pathogenesis in amyotrophic lateral sclerosis. A central role for calcium. Adv Neurol (2002) 0.77
Cellulose synthesized by Enterobacter sp. FY-07 under aerobic and anaerobic conditions. Bioresour Technol (2012) 0.77
The endowment effect can extend from self to mother: evidence from an fMRI study. Behav Brain Res (2013) 0.77
Major stressors facing patients with amyotrophic lateral sclerosis (ALS): a survey to identify their concerns and to compare with those of their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 0.76
Gypenoside Protects against Myocardial Ischemia-Reperfusion Injury by Inhibiting Cardiomyocytes Apoptosis via Inhibition of CHOP Pathway and Activation of PI3K/Akt Pathway In Vivo and In Vitro. Cell Physiol Biochem (2016) 0.76
Amyotrophic lateral sclerosis, frontotemporal lobar dementia, and p62: a functional convergence? Neurology (2012) 0.76
MRI analysis of the ISOBAR TTL internal fixation system for the dynamic fixation of intervertebral discs: a comparison with rigid internal fixation. J Orthop Surg Res (2014) 0.75
Novel therapeutic targets in neurodegenerative diseases: lessons from amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep (2008) 0.75
[Clinical significance of secondary results from non-invasive prenatal testing]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2017) 0.75
Euthanasia and physician-assisted suicide in ALS: a commentary. Am J Hosp Palliat Care (2004) 0.75
Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection. Expert Opin Ther Targets (2014) 0.75